Search Results - "PASSAM, F. H"

Refine Results
  1. 1

    In vivo modulation of angiogenesis by beta 2 glycoprotein I by Passam, F.H, Qi, J.C, Tanaka, K, Matthaei, K.I, Krilis, S.A

    Published in Journal of autoimmunity (01-11-2010)
    “…Abstract Beta 2 glycoprotein I (β2GPI) is the major auto antigen in the antiphospholipid syndrome but also interacts with fibrinolytic and angiogenic proteins…”
    Get full text
    Journal Article
  2. 2

    The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma by Alexandrakis, M G, Passam, F H, Dambaki, C, Pappa, C A, Stathopoulos, E N

    Published in Journal of clinical pathology (01-08-2004)
    “…Aim: Angiogenesis correlates with disease progression in various haematological malignancies. This study investigated the association between microvascular…”
    Get full text
    Journal Article
  3. 3

    Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity by Alexandrakis, M.G., Passam, F.H., Sfiridaki, A., Kandidaki, E., Roussou, P., Kyriakou, D.S.

    Published in American journal of hematology (01-04-2003)
    “…Hepatocyte growth factor (HGF) has been shown to be involved in angiogenesis, epithelial cell proliferation, and osteoclast activation. HGF and its receptor…”
    Get full text
    Journal Article
  4. 4

    Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis by ALEXANDRAKIS, M.G., PASSAM, F.H., PERISINAKIS, K., GANOTAKIS, E., MARGANTINIS, G., KYRIAKOU, D.S., BOUROS, D.

    Published in Respiratory medicine (01-08-2002)
    “…Proinflammatory cytokines Interleukin-1 β (IL-1 β) and Interleukin-6 (IL-6) play a significant role in the pathogenetic processes related to various malignant…”
    Get full text
    Journal Article
  5. 5

    Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma by ALEXANDRAKIS, M. G, PASSAM, F. H, BOULA, A, CHRISTOPHORIDOU, A, ALOIZOS, G, ROUSSOU, P, KYRIAKOU, D. S

    Published in Annals of hematology (2003)
    “…Angiogenesis plays an important role in multiple myeloma (MM) progression. Various mitogens such as vascular endothelial growth factor (VEGF) and basic…”
    Get full text
    Journal Article
  6. 6

    The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma by Alexandrakis, M.G., Passam, F.H., Ganotakis, E.S., Sfiridaki, K., Xilouri, I., Perisinakis, K., Kyriakou, D.S.

    Published in Clinical and laboratory haematology (01-02-2003)
    “…Summary Interleukin‐6 (IL‐6) and acute phase proteins are commonly increased in patients with multiple myeloma. Several of these acute phase proteins are…”
    Get full text
    Journal Article
  7. 7

    Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post‐translational modification of beta 2 glycoprotein I by PASSAM, F. H., GIANNAKOPOULOS, B., MIRARABSHAHI, P., KRILIS, S. A.

    Published in Journal of thrombosis and haemostasis (01-07-2011)
    “…It has been well established that antiphospholipid antibodies and specifically those directed against beta 2 glycoprotein I (β2GPI) are pathogenic for the…”
    Get full text
    Journal Article
  8. 8

    Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival by Alexandrakis, M.G, Passam, F.H, Sfiridaki, K, Moschandrea, J, Pappa, C, Liapi, D, Petreli, E, Roussou, P, Kyriakou, D.S

    Published in Leukemia research (01-03-2004)
    “…Interleukin-18 (IL-18) plays a role in the host’s response to tumours and angiogenesis. We determined serum levels of IL-18, vascular endothelial growth factor…”
    Get full text
    Journal Article
  9. 9

    Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis by Passam, F H, Alexandrakis, M G, Moschandrea, J, Sfiridaki, A, Roussou, P A, Siafakas, N M

    “…Increased angiogenic activity has been demonstrated in lymphoproliferative diseases including Hodgkin's disease. In the current study, the levels of…”
    Get more information
    Journal Article
  10. 10

    Redox control of β2‐glycoprotein I–von Willebrand factor interaction by thioredoxin‐1 by PASSAM, F. H., RAHGOZAR, S., QI, M., RAFTERY, M. J, WONG, J. W. H., TANAKA, K., IOANNOU, Y., ZHANG, J. Y., GEMMELL, R., QI, J. C., GIANNAKOPOULOS, B., HUGHES, W. E., HOGG, P. J., KRILIS, S. A.

    Published in Journal of thrombosis and haemostasis (01-08-2010)
    “…Background: β2‐Glycoprotein I (β2GPI) is an abundant plasma protein that is closely linked to blood clotting, as it interacts with various protein and cellular…”
    Get full text
    Journal Article
  11. 11

    Quick detection of Leishmania in peripheral blood by flow cytometry. Is prestorage leucodepletion necessary for leishmaniasis prevention in endemic areas? by Kyriakou, D. S., Alexandrakis, M. G., Passam, F. H., Kourelis, T. V., Foundouli, P., Matalliotakis, E., Maniatis, A. N.

    Published in Transfusion medicine (Oxford, England) (01-04-2003)
    “…Leishmaniasis is a serious health problem in various endemic areas. There are reports that the parasite can be transmitted via blood transfusions. We studied…”
    Get full text
    Journal Article
  12. 12

    Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma by Alexandrakis, M.G., Kyriakou, D.S., Passam, F.H., Malliaraki, N., Christophoridou, A.V., Karkavitsas, N.

    Published in Clinical and laboratory haematology (01-06-2002)
    “…Technetium 99m‐2‐methoxyisobutil‐isonitrile (Tc‐99m‐MIBI), also called sestaMIBI, has been used successfully to detect malignant tumours at diagnosis…”
    Get full text
    Journal Article
  13. 13

    The assessment of proliferating cell nuclear antigen immunostaining in myelodysplastic syndromes and its prognostic significance by Alexandrakis, M G, Passam, F H, Dambaki, K, Passam, A M, Nalbanti, F, Stathopoulos, E S, Kyriakou, D S

    Published in European journal of histochemistry (01-01-2005)
    “…Several prognostic factors for patients with myelodysplastic syndromes (MDS) have been identified in previous years. In order to determine prognostic factors…”
    Get full text
    Journal Article
  14. 14

    Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines by ALEXANDRAKIS, M. G, PASSAM, F. H, SFIRIDAKI, A, PAPPA, C. A, MOSCHANDREA, J. A, KANDIDAKI, E, TSIRAKIS, G, KYRIAKOU, D. S

    “…Leptin, apart from the regulation of food intake, has been implicated in hematopoiesis, the immune response and angiogenesis. Leptin has been found to be…”
    Get full text
    Journal Article
  15. 15

    Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activity by Alexandrakis, M. G., Kyriakou, D. S., Passam, F. H., Malliaraki, N., Vlachonikolis, I. G., Karkavitsas, N.

    Published in Hematological oncology (01-03-2003)
    “…Urinary cross‐linked N‐telopeptide of type I collagen (NTx) has been reported to be a sensitive and specific marker of bone resorption in multiple myeloma…”
    Get full text
    Journal Article
  16. 16

    Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance by PASSAM, F. H., TSIRAKIS, G., BOULA, A., FRAGOU, A., CONSOLAS, I., ALEGAKIS, A., KYRIAKOU, D. S., ALEXANDRAKIS, M. G.

    Published in Clinical and laboratory haematology (01-12-2004)
    “…Summary The aim of this study was to assess circulating soluble intercellular adhesion molecule‐1 (sICAM‐1), soluble vascular cell adhesion molecule‐1…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment by PASSAM, F. H., SFIRIDAKI, A., PAPPA, C., KYRIAKOU, D., PETRELI, E., ROUSSOU, P. A., ALEXANDRAKIS, M. G.

    “…Summary Increased angiogenesis has been shown to be a feature of non‐Hodgkin lymphomas (NHL). In the current study, the pretreatment levels of circulating…”
    Get full text
    Journal Article
  19. 19

    β2‐glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain by YU, P., PASSAM, F. H., YU, D. M., DENYER, G., KRILIS, S. A.

    Published in Journal of thrombosis and haemostasis (01-07-2008)
    “…Background: Beta‐2 glycoprotein I (β2GPI) is a plasma glycoprotein which interacts with various proteins of the coagulation and fibrinolysis system. β2GPI has…”
    Get full text
    Journal Article
  20. 20

    Redox control of [beta]2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1 by Passam, F H, Rahgozar, S, Qi, M, Raftery, M J, Wong, J W H, Tanaka, K, Ioannou, Y, Zhang, J Y, Gemmell, R, Qi, J C, Giannakopoulos, B, Hughes, W E, Hogg, P J, Krilis, S A

    Published in Journal of thrombosis and haemostasis (01-08-2010)
    “…Background:[beta]2-Glycoprotein I ([beta]2GPI) is an abundant plasma protein that is closely linked to blood clotting, as it interacts with various protein and…”
    Get full text
    Journal Article